INTRODUCTION: mTOR activity is increased in advanced prostate cancer (CaP) as a result of a high rate of PTEN mutations. RAD001 (Everolimus) is a new orally available mTOR inhibitor. The objective of our study was to evaluate the effects of RAD001 on the growth of CaP in the bone, both alone and in combination with docetaxel and zoledronic acid. METHODS: C4-2 CaP cells were injected into tibiae of mice and the animals were treated with RAD001, docetaxel, and zoledronic acid alone or in combination. Histomorphometrical analysis, serum PSA measurements, bone mineral density (BMD), and microCT were used to determine the effects of treatment on tumor and bone. RESULTS: All three agents alone decreased tumor volume, and RAD001 and docetaxel also decreased levels of serum PSA by 68% and 65%, respectively (both P < 0.01). Combinations of the agents were more effective in decreasing tumor volume than single agents. Three-drug treatment showed the greatest effect: 64% inhibition versus control (P < 0.01). Treatment with RAD001 interfered with the weight loss associated with growth of this tumor in the bone (non-RAD001 groups: 4.0% decrease in body weight, P = 0.0014; RAD001 groups: increase of 3.6% in body weight, P = 0.0037). CONCLUSIONS: RAD001 inhibited growth of C4-2 cells in bone, an effect augmented by addition of docetaxel and zoledronic acid. Moreover RAD001 had a significant impact on maintenance of body weight. RAD001 may hold promise for its effects on both metastatic CaP and the important syndrome of tumor cachexia. (c) 2008 Wiley-Liss, Inc.
INTRODUCTION:mTOR activity is increased in advanced prostate cancer (CaP) as a result of a high rate of PTEN mutations. RAD001 (Everolimus) is a new orally available mTOR inhibitor. The objective of our study was to evaluate the effects of RAD001 on the growth of CaP in the bone, both alone and in combination with docetaxel and zoledronic acid. METHODS: C4-2 CaP cells were injected into tibiae of mice and the animals were treated with RAD001, docetaxel, and zoledronic acid alone or in combination. Histomorphometrical analysis, serum PSA measurements, bone mineral density (BMD), and microCT were used to determine the effects of treatment on tumor and bone. RESULTS: All three agents alone decreased tumor volume, and RAD001 and docetaxel also decreased levels of serum PSA by 68% and 65%, respectively (both P < 0.01). Combinations of the agents were more effective in decreasing tumor volume than single agents. Three-drug treatment showed the greatest effect: 64% inhibition versus control (P < 0.01). Treatment with RAD001 interfered with the weight loss associated with growth of this tumor in the bone (non-RAD001 groups: 4.0% decrease in body weight, P = 0.0014; RAD001 groups: increase of 3.6% in body weight, P = 0.0037). CONCLUSIONS: RAD001 inhibited growth of C4-2 cells in bone, an effect augmented by addition of docetaxel and zoledronic acid. Moreover RAD001 had a significant impact on maintenance of body weight. RAD001 may hold promise for its effects on both metastatic CaP and the important syndrome of tumor cachexia. (c) 2008 Wiley-Liss, Inc.
Authors: Karin G Hermans; Dirk C van Alewijk; Joris A Veltman; Wytske van Weerden; Ad Geurts van Kessel; Jan Trapman Journal: Genes Chromosomes Cancer Date: 2004-03 Impact factor: 5.006
Authors: Viktor Grünwald; Linda DeGraffenried; Douglas Russel; William E Friedrichs; Ratna B Ray; Manuel Hidalgo Journal: Cancer Res Date: 2002-11-01 Impact factor: 12.701
Authors: Eva Corey; Janna E Quinn; Franck Bladou; Lisha G Brown; Martine P Roudier; Julie M Brown; Kent R Buhler; Robert L Vessella Journal: Prostate Date: 2002-06-01 Impact factor: 4.104
Authors: M S Neshat; I K Mellinghoff; C Tran; B Stiles; G Thomas; R Petersen; P Frost; J J Gibbons; H Wu; C L Sawyers Journal: Proc Natl Acad Sci U S A Date: 2001-08-14 Impact factor: 11.205
Authors: Eva Corey; Lisha G Brown; Janna E Quinn; Martin Poot; Martine P Roudier; Celestia S Higano; Robert L Vessella Journal: Clin Cancer Res Date: 2003-01 Impact factor: 12.531
Authors: Kevin D Courtney; Judith B Manola; Aymen A Elfiky; Robert Ross; William K Oh; Jeffrey T Yap; Annick D Van den Abbeele; Christopher W Ryan; Tomasz M Beer; Massimo Loda; Carmen Priolo; Philip Kantoff; Mary-Ellen Taplin Journal: Clin Genitourin Cancer Date: 2014-10-22 Impact factor: 2.872